CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB2093 : II-18]

21631 Ibusuki R, Iwama E, Shimauchi A, Tsutsumi H, Yoneshima Y, Tanaka K, Okamoto I. TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer. NPJ Precis Oncol 2024 8(1):60 PubMed ID: 38431700 DOI: 10.1038/s41698-024-00557-2

19849 Hirayama A, Tanaka K, Tsutsumi H, Nakanishi T, Yamashita S, Mizusaki S, Ishii Y, Ota K, Yoneshima Y, Iwama E, Okamoto I. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β Front Immunol 2023 14:1192861 PubMed ID: 37441079 DOI: 10.3389/fimmu.2023.1192861

21042 Tsutsumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, Inoue H, Tanaka K, Nakanishi Y, Okamoto I. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Lung Cancer 2023 175:101-111 PubMed ID: 36495783 DOI: 10.1016/j.lungcan.2022.11.018

21347 Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y. L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell Rep Med 2023 101142 PubMed ID: 37557179 DOI: 10.1016/j.xcrm.2023.101142

21446 Nakajima M, Tanaka K, Yoneshima Y, Yamashita S, Shibahara D, Iwama E, Okamoto I. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells. Biochem Biophys Res Commun 2023 681:120-126 PubMed ID: 37774569 DOI: 10.1016/j.bbrc.2023.09.067

20501 Yasuda Y, Nagano T, Jimbo N, Kiriu T, Suraya R, Hazama D, Yamamoto M, Maniwa Y, Nishimura Y, Kobayashi K. Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma. Anticancer Res 2022 42(1):271-277 PubMed ID: 34969734 DOI: 10.21873/anticanres.15482

18209 Conlon NT, Kooijman JJ, van Gerwen SJC, Mulder WR, Zaman GJR, Diala I, Eli LD, Lalani AS, Crown J, Collins DM. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors Br J Cancer 2021 124(7):1249-1259 PubMed ID: 33473169 DOI: 10.1038/s41416-020-01257-x

20304 Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K. Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients. Lung Cancer 2021 158:115-125 PubMed ID: 34157583 DOI: 10.1016/j.lungcan.2021.06.011

13215 Miwa N, Nagano T, Jimbo N, Dokuni R, Kiriu T, Mimura C, Yasuda Y, Katsurada M, Yamamoto M, Tachihara M, Tanaka Y, Kobayashi K, Itoh T, Maniwa Y, Nishimura Y. Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma. Onco Targets Ther 2020 PubMed ID: 32982291 DOI: 10.2147/OTT.S265539

14832 Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y. Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines Arch Virol 2020 165(1):207-214 PubMed ID: 31776677 DOI: 10.1007/s00705-019-04474-9

4872 Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression. Mol Cancer Ther 2019 18(8):1366-1373 PubMed ID: 31092564 DOI: 10.1158/1535-7163.MCT-18-0976

11040 Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada, Yasushi Yoshimura Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion BMC Cancer 2019 19(1):301 PubMed ID: 30943926 DOI: 10.1186/s12885-019-5527-2

10768 Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y. Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Sci Rep 2018 8:3482 PubMed ID: 29472726 DOI: 10.1038/s41598-018-21161-y

10411 Kunimasa K, Nagano T, Shimono Y, Dokuni R, Kiriu T, Tokunaga S, Tamura D, Yamamoto M, Tachihara M, Kobayashi K, Satouchi M, Nishimura Y. Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. Cancer Sci. 2017 108:1368-1377 PubMed ID: 28445002 DOI: 10.1111/cas.13266

12672 Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors Oncologist 2016 21(2):156-64 PubMed ID: 26768482 DOI: 10.1634/theoncologist.2015-0288

14941 Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T. A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer Int J Oncol 2015 46(2):497-504 PubMed ID: 25532027 DOI: 10.3892/ijo.2014.2787

16538 Shimomura M, Yaoi T, Itoh K, Kato D, Terauchi K, Shimada J, Fushiki S. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines Int J Oncol 2012 40(4):995-1004 PubMed ID: 22179563 DOI: 10.3892/ijo.2011.1297

8277 Shirogane Y, Takeda M, Tahara M, Ikegame S, Nakamura T, Yanagi Y. Epithelial-mesenchymal transition abolishes the susceptibility of polarized epithelial cell lines to measles virus. J. Biol. Chem. 2010 285:20882-90 PubMed ID: 20435897 DOI: 10.1074/jbc.M110.102590

6410 Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y. Is parainfluenza virus a threatening virus for human cancer cell lines? Hum Cell 2009 22(3):81-4 PubMed ID: 19624309 DOI: 10.1111/j.1749-0774.2009.00071.x

18309 Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res 2008 68(5):1303-9 PubMed ID: 18316592 DOI: 10.1158/0008-5472.CAN-07-5003